P
Parag R Gajendragadkar
Researcher at University of Oxford
Publications - 42
Citations - 943
Parag R Gajendragadkar is an academic researcher from University of Oxford. The author has contributed to research in topics: Catheter ablation & Ablation. The author has an hindex of 14, co-authored 42 publications receiving 693 citations. Previous affiliations of Parag R Gajendragadkar include British Heart Foundation & John Radcliffe Hospital.
Papers
More filters
Journal ArticleDOI
Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European Society of Cardiology.
Guilherme Pessoa-Amorim,Christian F. Camm,Christian F. Camm,Parag R Gajendragadkar,Parag R Gajendragadkar,Parag R Gajendragadkar,Giovanni Luigi De Maria,Giovanni Luigi De Maria,Celine Arsac,Cécile Laroche,José Luis Zamorano,Franz Weidinger,Stephan Achenbach,Aldo P. Maggioni,Chris P Gale,Chris P Gale,Athena Poppas,Barbara Casadei,Barbara Casadei,Barbara Casadei +19 more
TL;DR: The survey indicates that the impact of COVID-19 on STEMI presentations is likely to be substantial, with both lower presentations and a higher rate of delayed presentations occurring.
Journal ArticleDOI
Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure.
Giacomo Pucci,Joseph Cheriyan,Annette Hubsch,Stacey S. Hickson,Parag R Gajendragadkar,Tim Watson,Michael O'Sullivan,J. Woodcock-Smith,Giuseppe Schillaci,Ian B. Wilkinson,Carmel M. McEniery +10 more
TL;DR: The Vicorder and SphygmoCor devices provide reliable estimates of cSBP when calibrated to invasive pressure, which may be a simple alternative to tonometry-based methods for noninvasive assessment of cBP.
Journal ArticleDOI
Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial.
Parag R Gajendragadkar,Annette Hubsch,Kaisa M. Mäki-Petäjä,Martin Serg,Ian B. Wilkinson,Joseph Cheriyan +5 more
TL;DR: Lycopene supplementation improves endothelial function in CVD patients on optimal secondary prevention, but not in HVs.
Journal ArticleDOI
Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease
Marie Fisk,Parag R Gajendragadkar,Kaisa M. Mäki-Petäjä,Ian B. Wilkinson,Ian B. Wilkinson,Joseph Cheriyan,Joseph Cheriyan +6 more
TL;DR: An update of human clinical trial experience encompassing a clinically orientated approach, dedicated to cardiovascular disease follows, which provides a current perspective of the therapeutic potential of p38 MAPK inhibitors in the cardiovascular domain, including safety, tolerability, and pharmacokinetics.
Journal ArticleDOI
First clinical use of novel ablation catheter incorporating local impedance data.
Claire A. Martin,Ruairidh Martin,Parag R Gajendragadkar,Philippe Maury,Masateru Takigawa,Ghassen Cheniti,Antonio Frontera,Takeshi Kitamura,Josselin Duchateau,Konstantinos Vlachos,Felix Bourier,Anna Lam,Stephen R. Lord,Stephen Murray,Ewen Shephard,Thomas Pambrun,Arnaud Denis,Nicolas Derval,Mélèze Hocini,Michel Haïssaguerre,Pierre Jaïs,Frederic Sacher +21 more
TL;DR: First worldwide use of the Intellanav MiFi OI catheter is reported, providing ultra‐high density mapping and incorporating a “DirectSense” algorithm to measure local tissue impedance (LI).